Shanghai Kaibao Pharmaceutical: Announcement regarding winning the second prize of the National Science and Technology Progress Award
Shanghai Kaibao Pharmaceutical: Announcement of Annual Equity Distribution Implementation in 2023
Shanghai Kaibao Pharmaceutical: Legal Opinion of Tongli Law Firm in Shanghai on the Annual Shareholders Meeting of Shanghai Kaibao Pharmaceutical Co., Ltd. in 2023.
Shanghai Kaibao Pharmaceutical: Announcement of Resolutions of the Shareholders' Meeting for the Fiscal Year 2023
Shanghai Kaibao Pharmaceutical: Announcement on resignation of directors and by-election of directors
Shanghai Kaibao Pharmaceutical: Announcement on Additional Provisional Proposals for the 2023 Annual General Meeting of Shareholders and Supplementary Notice to the Shareholders' Meeting
Shanghai Kaibao Pharmaceutical: Announcement of Resolutions of the Fourth (Interim) Meeting of the Sixth Board of Directors
Shanghai Kaibao Pharmaceutical: 300039 Shanghai Kaibao Investor Relations Management Information 20240510
Shanghai Kaibao Pharmaceutical: Announcement on the company's acquisition of a real estate title certificate
Shanghai Kaibao Pharmaceutical: Rules of Work for the Nomination Committee of the Board of Directors (April 2024)
Shanghai Kaibao Pharmaceutical: Foreign Investment Management System (April 2024)
Shanghai Kaibao Pharmaceutical: Board Remuneration and Assessment Committee Work Rules (April 2024)
Shanghai Kaibao Pharmaceutical: Independent Director Work System (April 2024)
Shanghai Kaibao Pharmaceutical: Announcement on the renewal of the 2024 Audit Institution
Shanghai Kaibao Pharmaceutical: Report on the work of the Board of Supervisors for the year 2023
Shanghai Kaibao Pharmaceutical: 2023 Independent Director Debriefing Report (Jenny Lee)
Shanghai Kaibao Pharmaceutical: Board Strategy Committee Work Rules (April 2024)
Shanghai Kaibao Pharmaceutical: Internal Audit System (April 2024)
Shanghai Kaibao Pharmaceutical: Related Transaction Decision System (April 2024)
Shanghai Kaibao Pharmaceutical: 2023 Independent Director Debriefing Report (Tao Jiansheng)
No Data